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Abstract
Background—Pentavalent rotavirus vaccine (RV5) was recommended for routine use in 2006 
followed by monovalent rotavirus vaccine (RV1) in 2008.
Purpose—To describe, among a U.S. sample of pediatricians (n=289 respondents) and family 
medicine physicians (n=243 respondents), (1) current practices regarding rotavirus vaccine (RV) 
and barriers to use with comparison to a 2007 survey and (2) knowledge of recent safety concerns 
regarding RV1 and their impact on its use.
Methods—A mail and Internet survey was conducted with the physicians, from November 2010 
to January 2011; analyses were conducted March–September 2011.
Results—Response rates were 70% (289/410) for pediatricians and 61% (243/401) for family 
medicine physicians; routine administration of RV was reported by 95% of pediatricians and 65% 
of family medicine physicians (2007: 85% and 45%). Almost all barriers to use of RV had 
decreased compared to 2007. For pediatricians and family medicine physicians, respectively, 94% 
and 70% were aware of the temporary suspension of RV1 due to presence of porcine circovirus; 
49% and 45%, respectively, were aware of the addition to RV1 labeling regarding a possible 
increased risk of intussusception. Among physicians aware of the safety issues, <5% reported 
stopping giving RV as a result. After reading information about porcine circovirus, 35% of 
pediatricians and 59% of family medicine physicians reported it had increased their own concerns 
about the safety of RV; and 31% and 60%, respectively, reported this regarding intussusception.
Conclusions—The acceptance of RV has increased, and barriers to use have decreased. Among 
physicians, recent safety questions about RV1 have not affected use of RV, although they have 
raised safety concerns.
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Introduction
The first rotavirus vaccine (RotaShield, Wyeth-Lederle) was licensed and recommended for 
routine use by the U.S. Advisory Committee on Immunization Practices (ACIP) and the 
American Academy of Pediatrics, Committee on Infectious Diseases (AAP-COID), in 1998 
but was withdrawn from the market within 1 year after it was associated with an increased 
risk of intussusception.1,2 A study in 2003 suggested that pediatricians would use a new 
rotavirus vaccine if it were safer than RotaShield and was recommended routinely by the 
AAP and the ACIP.3 Two other rotavirus vaccines—a pentavalent rotavirus vaccine (RV5, 
RotaTeq, Merck and Co.) and a monovalent rotavirus vaccine (RV1; Rotarix, GSK 
Biologicals)—were in development at the time, and each underwent extensive prelicensure 
testing looking specifically for an increased risk of intussusception. None was found.4,5
The ACIP made a formal recommendation to include RV5 as part of the routine infant series 
in February 2006,6 and updated the recommendation in June 2008 to include RV1.7 Since 
the recommendation of RV5 and RV1, their use in routine practice occurred relatively 
rapidly among pediatricians and to a lesser extent among family physicians.8 The impact of 
the vaccines in reducing hospitalizations and outpatient visits in the U.S. has been 
substantial.9–15
However, two recent findings have raised potential concerns about the safety of current 
rotavirus vaccines. In March 2010, the U.S Food and Drug Administration (FDA) 
recommended temporarily suspending use of RV1 because of the detection of porcine 
circovirus, a nonhuman pathogen, in the vaccine.16 Genetic material of porcine circovirus 
later was identified also in RV5. A subsequent FDA review concluded that the presence of 
porcine circovirus likely posed no threat to human health, and the temporary suspension of 
RV1 use was lifted in May 2010. Shortly thereafter, in August 2010, the Global Advisory 
Committee on Vaccine Safety of the WHO reviewed preliminary data from postmarketing 
studies that showed a possible increased risk of intussusception with RV1 in certain 
populations.17 On September 22, 2010, the FDA recommended a label change for RV1 
advising providers of the new data.18
Given that the observed health benefits of rotavirus vaccination far exceed the potential 
risks, the ACIP and other international health bodies have made no changes to the 
recommendations to routinely vaccinate against rotavirus. However, the extent to which 
these safety concerns have affected physicians’ opinions and use of rotavirus vaccine is 
unknown. The objectives of the current study were to assess, through a national survey of 
pediatricians and family medicine physicians, (1) trends in attitudes and practices regarding 
rotavirus vaccine and barriers to its use through comparison with a survey conducted prior to 
the new safety concerns; (2) physicians’ perceptions of rotavirus vaccine effectiveness; (3) 
physicians’ knowledge and perception of parents’ knowledge about the recent safety 
concerns and its impact on their attitudes and practice regarding rotavirus vaccine.
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Methods
Study Setting
From November 2010 to January 2011, a mail and Internet survey was conducted regarding 
the rotavirus vaccines in a nationwide sample of pediatricians (n=289 respondents) and 
family medicine physicians (n=243 respondents). The present study was reviewed and 
approved for exempt status by the Colorado Multiple IRB, and informed consent was not 
required.
Population
As part of the Vaccine Policy Collaborative Initiative,19 a national network of primary care 
physicians was developed through recruitment of family medicine physicians and 
pediatricians from the American Academy of Family Physicians (AAFP) and the American 
Academy of Pediatrics (AAP), respectively. Quota sampling19,20 was performed to make 
sure that physicians in the networks were similar to AAFP and AAP memberships with 
respect to the region of the country, urban versus rural location, and practice type. Physicians 
in the network were compared to physicians in the same specialty randomly sampled from 
the American Medical Association Physician Master File and were generally similar with 
regard to demographic characteristics, practice attributes, and reported attitudes regarding a 
range of vaccination issues.19 In addition, this national network of primary care physicians 
allows documentation of demographic data of both respondents and nonrespondents.
Survey Design
The survey was pretested with a panel of six pediatricians and six family medicine 
physicians and then piloted among 23 pediatricians and 21 family medicine physicians from 
different regions of the country. Questions regarding practices and barriers to the use of 
rotavirus vaccine were based on a prior survey by the current authors’ group from 20078; 
respondents used 4-point Likert-type scales for their answers. New questions using 4-point 
Likert-type scales assessed physician knowledge of rotavirus vaccine effectiveness, 
physician and perceived parental knowledge of the new information regarding porcine 
circovirus and intussusception, and the impact of a temporary suspension and a change in 
labeling on providers’ use of rotavirus vaccines.
The Likert-type scales regarding practices and attitudes were classified from strongly agree 
to strongly disagree. The Likert scales regarding barriers were classified from definitely a 
barrier to not a barrier at all. For the Results section and for Figures 1 and 2, responses were 
collapsed as strongly or somewhat agree and somewhat or definitely a barrier.
Survey Administration
Physicians were surveyed through the Internet or by mail depending on preference. The 
Internet survey was administered using Vovici, a web-based program. The Internet 
respondent group received an initial e-mail and up to nine e-mail reminders to complete the 
survey, and the mail group received up to three surveys by mail. Subjects in the Internet 
group received two final paper surveys by mail if they had not responded to e-mail 
reminders.
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Data Analysis
Internet and mail surveys were pooled for all analyses, as physician attitudes assessed with 
the two methods have been found to be comparable.21 Chi-squared and Wilcoxon rank-sum 
tests were used for comparisons of characteristics of respondents and nonrespondents and 
Kolmogorov–Smirnov (KS) tests for comparisons of overall distributions of responses 
between respondents in the two specialties. All analyses were conducted March through 
September 2011 and were performed using SAS, version 9.2.
Results
Response Rates and Study Sample
Response rates were 70% (289/410) for pediatricians and 61% (243/401) for family 
medicine physicians. Fifty-one family medicine physicians and four pediatricians were 
excluded because they reported not seeing infants aged <6 months, leaving a final analysis 
cohort of 477. Respondents were similar to nonrespondents, except for differences among 
family medicine physicians in practice setting and region of the country (Table 1). Also 
shown in Table 1 are other characteristics of respondents’ practices.
Trends in Use of, Attitudes Regarding, and Perceived Barriers to Use of Rotavirus Vaccine
Pediatricians more often reported strongly recommending the vaccine, whereas family 
medicine physicians were more likely to report informing parents about the vaccine but 
making no recommendation (Figure 1). Few physicians reported recommending against the 
vaccine. For both specialties, more providers were strongly recommending the vaccine in 
2010 than in 2007. Ninety-five percent of pediatricians and 65% of family medicine 
physicians reported that they routinely administer rotavirus vaccine to all eligible infants 
whose parents consent (85% and 45% in 2007), whereas 27% of family physicians and 4% 
of pediatricians reported that they do not administer rotavirus vaccine (42% and 11% in 
2007) (p<0.001 for both differences between specialties and years).
Compared to 2007, more physicians in both specialties endorsed positive attitudes toward 
rotavirus vaccine in 2010 (Appendix A, available online at www.ajpmonline.org). Most 
physicians strongly or somewhat agreed that “because rotavirus infections are common and 
potentially severe in the U.S., there is a need for a safe and effective rotavirus vaccine” and 
also with the ACIP’s recommendation that rotavirus vaccine should be routinely 
recommended for all eligible infants.
Statements related to perceived parental concern about safety were the most commonly 
identified barriers by all physicians (Figure 2). For all barriers presented, the percentage of 
physicians reporting definitely or somewhat of a barrier decreased from 2007 to 2010 with 
one exception: 42% of pediatricians in 2010 reported that “Parents’ concern about the safety 
of vaccines in general” was definitely or somewhat of a barrier compared to 35% in 2007 
(p=NS).
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Perception of Rotavirus Vaccine Effectiveness
Compared to family medicine physicians, pediatricians more often strongly or somewhat 
agreed with the statement, “Rotavirus vaccine has resulted in marked decreases in 
hospitalizations and emergency room visits for diarrhea in the United States” (95% vs 66%, 
p<0.001). In bivariate analysis among family medicine physicians, among those who 
reported administering rotavirus vaccine, 75% strongly or somewhat agreed with the 
preceding statement compared to 40% who reported not administering the vaccine 
(p<0.001).
Physician Knowledge of U.S. Food and Drug Administration Recommendations
Among physicians who reported administering any rotavirus vaccine as of March 2010 
(n=397), 94% of pediatricians and 70% of family medicine physicians reported having heard 
about the FDA’s recommendation to temporarily suspend the use of RV1 because of the 
presence of porcine circovirus (p<0.001). Among physicians who reported administering 
any rotavirus vaccine and who reported that they had heard about the FDA’s 
recommendation to temporarily suspend the use of RV1 because of the presence of porcine 
circovirus (n=337), 68% of pediatricians and 53% of family medicine physicians reported 
that they did not alter their practice, as they were already using only RV5; 28% of 
pediatricians and 25% of family physicians reporting that they stopped using RV1 and gave 
only RV5; and 4% of pediatricians and 19% of family physicians reported that they 
temporarily stopped giving any rotavirus vaccine (p<0.001). Among the same group of 
physicians who reported having heard about the suspension of RV1 (n=337), at least 6 
months after the FDA’s announcement that it was appropriate to resume use of both 
rotavirus vaccines, 78% of pediatricians and 67% of family physicians reported that they 
were administering RV5 only, although 1% and 6%, respectively, reported no longer 
administering any rotavirus vaccine (p=0.002).
Physician Knowledge of Labeling Change
A total of 49% of pediatricians and 45% of family physicians reported having heard about 
the FDA’s addition to the warnings and precautions section of the RV1 labeling regarding a 
possible increased risk of intussusception (p=0.51). After reading an explanation about these 
labeling changes, all physicians were asked to respond to a question assessing the impact of 
these changes. As with the questions regarding porcine circovirus, most physicians who 
reported that they were administering any rotavirus vaccine were administering RV5 and 
would not alter their practice (pediatricians, 72%; family physicians, 45%; p<0.001). A total 
of 4% from each speciality reported that they had stopped or would stop giving RV1 and 
give only RV5, and 2% of family medicine physicians and 1% of pediatricians reported that 
they had stopped or would stop giving any rotavirus vaccine based on the information about 
intussusception.
Physicians’ Attitudes and Perceptions of Parental Knowledge
The majority of both specialties agreed that most parents were unaware of either the FDA’s 
recommendation to temporarily suspend the use of RV1 because of the presence of porcine 
circovirus or the possible association of RV1 with intussusception (Appendix B, available 
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online at www.ajpmonline.org). The majority of both specialties reported that the 
information about a possible association of RV1 and intussusception had increased their own 
concerns about the safety of RV1, and 60% of family medicine physicians and 30% of 
pediatricians reported that it had increased their own concerns about the safety of both 
rotavirus vaccines.
Discussion
This nationally representative survey of pediatricians and family medicine physicians found 
that for most physicians, the recent information about porcine circovirus and a possible 
increased risk of intussusception and the subsequent FDA actions had little impact on their 
practice, and most physicians report that questions from parents regarding these issues were 
uncommon. However, the new information appears to have increased physicians’ concerns 
about the safety of rotavirus vaccine, particularly family medicine physicians.
The study also shows that acceptance and use of rotavirus vaccines has increased during the 
5 years since the ACIP recommendation, with 95% of pediatricians reporting routinely 
administering rotavirus vaccine to all eligible infants. These changing attitudes and 
acceptance of the vaccine have translated into relatively rapid increases in RV coverage.22 
However, less than half of family medicine physicians report strongly recommending the 
vaccine, and only 65% routinely administer the vaccine; thus, efforts to increase acceptance 
and use of rotavirus vaccine must continue.
Barriers to use of rotavirus vaccine have decreased in both specialties. The decreases in 
financial barriers are particularly encouraging, as these were among the most commonly 
endorsed in 2007. This decrease is likely due to virtually all insurance companies now 
covering the vaccine. Physician attitudes regarding rotavirus vaccine also have decreased as 
reported barriers, a finding that probably is related both to experience with the vaccine and 
knowledge of its impact. Physicians’ report of a continuing high level of parental concern 
regarding vaccine safety in general is consistent with other studies,23 although it is 
encouraging that few physicians reported parental concern specifically about rotavirus 
vaccine.
As with other studies on the adoption of new vaccines,24–26 there were important differences 
between family medicine physicians and pediatricians in practices and attitudes regarding 
rotavirus vaccine. Although both specialties are more likely to administer rotavirus vaccine 
now than they were 5 years ago, pediatricians are substantially more likely to use the 
vaccine, report a higher level of confidence in the effectiveness of rotavirus vaccine, and feel 
favorable about the vaccine. Reasons for differences in adoption between the specialties are 
likely fueled by a variety of issues that have been discussed previously in the literature.8 The 
current data also suggest that, in the case of rotavirus, lack of awareness of the data 
demonstrating effectiveness of the vaccine also appears to be a factor associated with lower 
use by family medicine physicians.
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Limitations
The current study has some important limitations. First, survey respondents may have 
differed from nonrespondents. In addition, this survey was based on sentinel physician 
networks from the AAP and AAFP, and members of these organizations may have had 
different experiences or perceptions than nonmembers. Also, the survey took place at the 
end of 2010, 3 months and 6 months after the actions by the FDA regarding intussusception 
and porcine circovirus, respectively, so parents and physicians may not yet have heard about 
these actions. In addition, because many of the respondents had not heard of the recent 
actions by the FDA, their responses were based on reading an informational statement 
provided in the survey. Their responses might have differed if they had received the 
information from other sources. Finally, the survey relied on self-report rather than 
observation of practice.
Conclusion
The acceptance and use of rotavirus vaccines have increased since the ACIP 
recommendation and barriers to use, particularly financial ones, have decreased greatly. The 
recent publicity about potential safety concerns does not appear to have had a negative 
impact on physician acceptance of rotavirus vaccine, or vaccine administration practices of 
physicians, although it has raised safety concerns among some physicians, especially those 
in family medicine. With providers reporting increasing parental concern with vaccine 
safety,23 physicians’ confidence in the safety and importance of vaccines assumes even 
greater importance than in the past. There will be an ongoing need to assess the impact of 
increased safety concerns among providers on vaccine use.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Current practice with respect to recommending rotavirus vaccination among pediatricians 
and family medicine physicians
Note: p<0.0001 for KS test for comparison of distributions of responses between Peds and 
FM in both 2007 and 2010 results; p<0.001 for FM and p=0.002 for Peds for KS test 
comparison of distributions of responses between 2007 and 2010.
FM, family medicine physicians; KS, Kolmogorov-Smirnov; Peds, pediatricians
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Figure 2. 
Reported barriers to administering rotavirus vaccine, percentage of physicians reporting 
somewhat of a barrier or definitely a barrier
Note: p<0.05 for McNemar’s test for differences between 2007 and 2010 for both 
specialties, unless otherwise noted.
aThis question was not asked in the 2007 survey.
*p=NS for McNemar’s test for difference between 2007 and 2010 for both specialties.
**p=NS for McNemar’s test for difference between 2007 and 2010 for Peds, p<0.05 for FM.
***p=NS for McNemar’s test for difference between 2007 and 2010 for FM, p<0.05 for 
Peds.
FM, family medicine physicians; Peds, pediatricians
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